Jannis Müller,Sifat Sharmin,Johannes Lorscheider,Serkan Ozakbas,Rana Karabudak,Dana Horakova,Bianca Weinstock-Guttman,Vahid Shaygannejad,Masoud Etemadifar,Raed Alroughani,Francesco Patti,Sara Eichau,Alexandre Prat,Alessandra Lugaresi,Valentina Tomassini,Allan G Kermode,Maria Pia Amato,Recai Turkoglu,Ayse Altintas,Katherine Buzzard,Aysun Soysal,Anneke van der Walt,Helmut Butzkueven,Yolanda Blanco,Oliver Gerlach,Samia J Khoury,Michael Barnett,Nevin John,Jeannette Lechner-Scott,Matteo Foschi,Andrea Surcinelli,Vincent van Pesch,Julie Prevost,Maria Jose Sa,Davide Maimone,Marie D'hooghe,Stella Hughes,Suzanne Hodgkinson,Chris McGuigan,Elisabetta Cartechini,Bruce Taylor,Daniele Spitaleri,Mark Slee,Pamela McCombe,Bassem Yamout,Pascal Benkert,Jens Kuhle,Ludwig Kappos,Izanne Roos,Tomas Kalincik,,Eva Kubala Havrdova,Marc Girard,Pierre Duquette,Marzena Fabis-Pedrini,William M Carroll,Olga Skibina,Riadh Gouider,Saloua Mrabet,Cristina Ramo-Tello,Claudio Solaro,Mario Habek,Bart Van Wijmeersch,Radek Ampapa,Richard Macdonell,Celia Oreja-Guevara,Koen de Gans,Guy Laureys,Jiwon Oh,Justin Garber,Orla Gray,Eduardo Agüera-Morales,Jose Luis Sanchez-Menoyo,Tamara Castillo-Triviño,Nikolaos Grigoriadis,Thor Petersen,Todd A Hardy,Steve Vucic,Stephen Reddel,Sudarshini Ramanathan,Abdullah Al-Asmi,Mihaela Simu,Seyed Mohammad Baghbanian,Dieter Poehlau,Talal Al-Harbi,Juan Ignacio Rojas,Norma Deri,Patrice Lalive,Melissa Cambron,Tunde Csepany,Neil Shuey,Barbara Willekens,Cameron Shaw,Danny Decoo,Jennifer Massey,Özgür Yaldizli,Tobias Derfuss,Cristina Granziera
{"title":"复发缓解型多发性硬化症中独立于复发活动的进展(PIRA)的标准化定义。","authors":"Jannis Müller,Sifat Sharmin,Johannes Lorscheider,Serkan Ozakbas,Rana Karabudak,Dana Horakova,Bianca Weinstock-Guttman,Vahid Shaygannejad,Masoud Etemadifar,Raed Alroughani,Francesco Patti,Sara Eichau,Alexandre Prat,Alessandra Lugaresi,Valentina Tomassini,Allan G Kermode,Maria Pia Amato,Recai Turkoglu,Ayse Altintas,Katherine Buzzard,Aysun Soysal,Anneke van der Walt,Helmut Butzkueven,Yolanda Blanco,Oliver Gerlach,Samia J Khoury,Michael Barnett,Nevin John,Jeannette Lechner-Scott,Matteo Foschi,Andrea Surcinelli,Vincent van Pesch,Julie Prevost,Maria Jose Sa,Davide Maimone,Marie D'hooghe,Stella Hughes,Suzanne Hodgkinson,Chris McGuigan,Elisabetta Cartechini,Bruce Taylor,Daniele Spitaleri,Mark Slee,Pamela McCombe,Bassem Yamout,Pascal Benkert,Jens Kuhle,Ludwig Kappos,Izanne Roos,Tomas Kalincik,,Eva Kubala Havrdova,Marc Girard,Pierre Duquette,Marzena Fabis-Pedrini,William M Carroll,Olga Skibina,Riadh Gouider,Saloua Mrabet,Cristina Ramo-Tello,Claudio Solaro,Mario Habek,Bart Van Wijmeersch,Radek Ampapa,Richard Macdonell,Celia Oreja-Guevara,Koen de Gans,Guy Laureys,Jiwon Oh,Justin Garber,Orla Gray,Eduardo Agüera-Morales,Jose Luis Sanchez-Menoyo,Tamara Castillo-Triviño,Nikolaos Grigoriadis,Thor Petersen,Todd A Hardy,Steve Vucic,Stephen Reddel,Sudarshini Ramanathan,Abdullah Al-Asmi,Mihaela Simu,Seyed Mohammad Baghbanian,Dieter Poehlau,Talal Al-Harbi,Juan Ignacio Rojas,Norma Deri,Patrice Lalive,Melissa Cambron,Tunde Csepany,Neil Shuey,Barbara Willekens,Cameron Shaw,Danny Decoo,Jennifer Massey,Özgür Yaldizli,Tobias Derfuss,Cristina Granziera","doi":"10.1001/jamaneurol.2025.0495","DOIUrl":null,"url":null,"abstract":"Importance\r\nProgression independent of relapse activity (PIRA) is a significant contributor to long-term disability accumulation in relapsing-remitting multiple sclerosis (MS). Prior studies have used varying PIRA definitions, hampering the comparability of study results.\r\n\r\nObjective\r\nTo compare various definitions of PIRA.\r\n\r\nDesign, Setting, and Participants\r\nThis cohort study involved a retrospective analysis of prospectively collected data from the MSBase registry from July 2004 to July 2023. The participants were patients with MS from 186 centers across 43 countries who had clinically definite relapsing-remitting MS, a complete minimal dataset, and 3 or more documented Expanded Disability Status Scale (EDSS) assessments.\r\n\r\nExposure\r\nThree-hundred sixty definitions of PIRA as combinations of the following criteria: baseline disability (fixed baseline with re-baselining after PIRA, or plus re-baselining after relapses, or plus re-baselining after improvements), minimum confirmation period (6, 12, or 24 months), confirmation magnitude (EDSS score at/above worsening score or at/above threshold compared with baseline), freedom from relapse at EDSS score worsening (90 days prior, 90 days prior and 30 days after, 180 days prior and after, since previous EDSS assessment, or since baseline), and freedom from relapse at confirmation (30 days prior, 90 days prior, 30 days before and after, or between worsening and confirmation).\r\n\r\nMain Outcome and Measure\r\nFor each definition, we quantified PIRA incidence and persistence (ie, absence of a 3-month confirmed EDSS improvement over ≥5 years).\r\n\r\nResults\r\nAmong 87 239 patients with MS, 33 303 patients fulfilled the inclusion criteria; 24 152 (72.5%) were female and 9151 (27.5%) were male. At the first visits, the mean (SD) age was 36.4 (10.9) years; 28 052 patients (84.2%) had relapsing-remitting MS, and the median (IQR) EDSS score was 2.0 (1.0-3.0). Participants had a mean (SD) 15.1 (11.9) visits over 8.9 (5.2) years. PIRA incidence ranged from 0.141 to 0.658 events per decade and persistence from 0.753 to 0.919, depending on the definition. In particular, the baseline and confirmation period influenced PIRA detection. The following definition yielded balanced incidence and persistence: a significant disability worsening compared with a baseline (reset after each PIRA event, relapse, and EDSS score improvement), in absence of relapses since the last EDSS assessment, confirmed with EDSS scores (not preceded by relapses within 30 days) that remained above the worsening threshold for at least 12 months.\r\n\r\nConclusion and Relevance\r\nIncidence and persistence of PIRA are determined by the definition used. The proposed standardized definition aims to enhance comparability among studies.","PeriodicalId":14677,"journal":{"name":"JAMA neurology","volume":"121 1","pages":""},"PeriodicalIF":20.4000,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.\",\"authors\":\"Jannis Müller,Sifat Sharmin,Johannes Lorscheider,Serkan Ozakbas,Rana Karabudak,Dana Horakova,Bianca Weinstock-Guttman,Vahid Shaygannejad,Masoud Etemadifar,Raed Alroughani,Francesco Patti,Sara Eichau,Alexandre Prat,Alessandra Lugaresi,Valentina Tomassini,Allan G Kermode,Maria Pia Amato,Recai Turkoglu,Ayse Altintas,Katherine Buzzard,Aysun Soysal,Anneke van der Walt,Helmut Butzkueven,Yolanda Blanco,Oliver Gerlach,Samia J Khoury,Michael Barnett,Nevin John,Jeannette Lechner-Scott,Matteo Foschi,Andrea Surcinelli,Vincent van Pesch,Julie Prevost,Maria Jose Sa,Davide Maimone,Marie D'hooghe,Stella Hughes,Suzanne Hodgkinson,Chris McGuigan,Elisabetta Cartechini,Bruce Taylor,Daniele Spitaleri,Mark Slee,Pamela McCombe,Bassem Yamout,Pascal Benkert,Jens Kuhle,Ludwig Kappos,Izanne Roos,Tomas Kalincik,,Eva Kubala Havrdova,Marc Girard,Pierre Duquette,Marzena Fabis-Pedrini,William M Carroll,Olga Skibina,Riadh Gouider,Saloua Mrabet,Cristina Ramo-Tello,Claudio Solaro,Mario Habek,Bart Van Wijmeersch,Radek Ampapa,Richard Macdonell,Celia Oreja-Guevara,Koen de Gans,Guy Laureys,Jiwon Oh,Justin Garber,Orla Gray,Eduardo Agüera-Morales,Jose Luis Sanchez-Menoyo,Tamara Castillo-Triviño,Nikolaos Grigoriadis,Thor Petersen,Todd A Hardy,Steve Vucic,Stephen Reddel,Sudarshini Ramanathan,Abdullah Al-Asmi,Mihaela Simu,Seyed Mohammad Baghbanian,Dieter Poehlau,Talal Al-Harbi,Juan Ignacio Rojas,Norma Deri,Patrice Lalive,Melissa Cambron,Tunde Csepany,Neil Shuey,Barbara Willekens,Cameron Shaw,Danny Decoo,Jennifer Massey,Özgür Yaldizli,Tobias Derfuss,Cristina Granziera\",\"doi\":\"10.1001/jamaneurol.2025.0495\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Importance\\r\\nProgression independent of relapse activity (PIRA) is a significant contributor to long-term disability accumulation in relapsing-remitting multiple sclerosis (MS). Prior studies have used varying PIRA definitions, hampering the comparability of study results.\\r\\n\\r\\nObjective\\r\\nTo compare various definitions of PIRA.\\r\\n\\r\\nDesign, Setting, and Participants\\r\\nThis cohort study involved a retrospective analysis of prospectively collected data from the MSBase registry from July 2004 to July 2023. The participants were patients with MS from 186 centers across 43 countries who had clinically definite relapsing-remitting MS, a complete minimal dataset, and 3 or more documented Expanded Disability Status Scale (EDSS) assessments.\\r\\n\\r\\nExposure\\r\\nThree-hundred sixty definitions of PIRA as combinations of the following criteria: baseline disability (fixed baseline with re-baselining after PIRA, or plus re-baselining after relapses, or plus re-baselining after improvements), minimum confirmation period (6, 12, or 24 months), confirmation magnitude (EDSS score at/above worsening score or at/above threshold compared with baseline), freedom from relapse at EDSS score worsening (90 days prior, 90 days prior and 30 days after, 180 days prior and after, since previous EDSS assessment, or since baseline), and freedom from relapse at confirmation (30 days prior, 90 days prior, 30 days before and after, or between worsening and confirmation).\\r\\n\\r\\nMain Outcome and Measure\\r\\nFor each definition, we quantified PIRA incidence and persistence (ie, absence of a 3-month confirmed EDSS improvement over ≥5 years).\\r\\n\\r\\nResults\\r\\nAmong 87 239 patients with MS, 33 303 patients fulfilled the inclusion criteria; 24 152 (72.5%) were female and 9151 (27.5%) were male. At the first visits, the mean (SD) age was 36.4 (10.9) years; 28 052 patients (84.2%) had relapsing-remitting MS, and the median (IQR) EDSS score was 2.0 (1.0-3.0). Participants had a mean (SD) 15.1 (11.9) visits over 8.9 (5.2) years. PIRA incidence ranged from 0.141 to 0.658 events per decade and persistence from 0.753 to 0.919, depending on the definition. In particular, the baseline and confirmation period influenced PIRA detection. The following definition yielded balanced incidence and persistence: a significant disability worsening compared with a baseline (reset after each PIRA event, relapse, and EDSS score improvement), in absence of relapses since the last EDSS assessment, confirmed with EDSS scores (not preceded by relapses within 30 days) that remained above the worsening threshold for at least 12 months.\\r\\n\\r\\nConclusion and Relevance\\r\\nIncidence and persistence of PIRA are determined by the definition used. The proposed standardized definition aims to enhance comparability among studies.\",\"PeriodicalId\":14677,\"journal\":{\"name\":\"JAMA neurology\",\"volume\":\"121 1\",\"pages\":\"\"},\"PeriodicalIF\":20.4000,\"publicationDate\":\"2025-04-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAMA neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1001/jamaneurol.2025.0495\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamaneurol.2025.0495","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.
Importance
Progression independent of relapse activity (PIRA) is a significant contributor to long-term disability accumulation in relapsing-remitting multiple sclerosis (MS). Prior studies have used varying PIRA definitions, hampering the comparability of study results.
Objective
To compare various definitions of PIRA.
Design, Setting, and Participants
This cohort study involved a retrospective analysis of prospectively collected data from the MSBase registry from July 2004 to July 2023. The participants were patients with MS from 186 centers across 43 countries who had clinically definite relapsing-remitting MS, a complete minimal dataset, and 3 or more documented Expanded Disability Status Scale (EDSS) assessments.
Exposure
Three-hundred sixty definitions of PIRA as combinations of the following criteria: baseline disability (fixed baseline with re-baselining after PIRA, or plus re-baselining after relapses, or plus re-baselining after improvements), minimum confirmation period (6, 12, or 24 months), confirmation magnitude (EDSS score at/above worsening score or at/above threshold compared with baseline), freedom from relapse at EDSS score worsening (90 days prior, 90 days prior and 30 days after, 180 days prior and after, since previous EDSS assessment, or since baseline), and freedom from relapse at confirmation (30 days prior, 90 days prior, 30 days before and after, or between worsening and confirmation).
Main Outcome and Measure
For each definition, we quantified PIRA incidence and persistence (ie, absence of a 3-month confirmed EDSS improvement over ≥5 years).
Results
Among 87 239 patients with MS, 33 303 patients fulfilled the inclusion criteria; 24 152 (72.5%) were female and 9151 (27.5%) were male. At the first visits, the mean (SD) age was 36.4 (10.9) years; 28 052 patients (84.2%) had relapsing-remitting MS, and the median (IQR) EDSS score was 2.0 (1.0-3.0). Participants had a mean (SD) 15.1 (11.9) visits over 8.9 (5.2) years. PIRA incidence ranged from 0.141 to 0.658 events per decade and persistence from 0.753 to 0.919, depending on the definition. In particular, the baseline and confirmation period influenced PIRA detection. The following definition yielded balanced incidence and persistence: a significant disability worsening compared with a baseline (reset after each PIRA event, relapse, and EDSS score improvement), in absence of relapses since the last EDSS assessment, confirmed with EDSS scores (not preceded by relapses within 30 days) that remained above the worsening threshold for at least 12 months.
Conclusion and Relevance
Incidence and persistence of PIRA are determined by the definition used. The proposed standardized definition aims to enhance comparability among studies.
期刊介绍:
JAMA Neurology is an international peer-reviewed journal for physicians caring for people with neurologic disorders and those interested in the structure and function of the normal and diseased nervous system. The Archives of Neurology & Psychiatry began publication in 1919 and, in 1959, became 2 separate journals: Archives of Neurology and Archives of General Psychiatry. In 2013, their names changed to JAMA Neurology and JAMA Psychiatry, respectively. JAMA Neurology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.